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Abstract
The transforming growth factor-L (TGFL) signaling pathway is one important player in the regulation of extracellular
matrix turnover and cell proliferation in epithelial regeneration. We used cerulein-induced pancreatitis in rats as a model to
investigate the regulation of TGFL receptor type I and type II expression on protein and messenger RNA level during
regeneration. In the regenerating pancreas, mRNA levels of TGFL receptor I and II were significantly increased with a
maximum after 2 days. On protein level, expression of TGFL receptor II was significantly increased after 3^5 days. This
elevated expression could be inhibited by neutralizing the endogenous biological activity of TGFL1 with a specific antibody.
In cultured pancreatic epithelial cells, TGFL1 reduced cell proliferation as measured by [3H]thymidine incorporation.
Furthermore the transcript levels of TGFL1 as well as mRNA and protein concentrations of type I and type II receptor
increased during TGFL stimulation in vitro. These results indicate that epithelial pancreatic cells contribute to the enhanced
TGFL1 synthesis during pancreatic regeneration by an autocrine mechanism. TGFL1, furthermore, upregulates the
expression of its own receptors during the regenerative process, thereby contributing to the increase of the TGFL-induced
cellular responses. ß 1999 Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The members of the transforming growth factor-L
family (TGFL) are important regulatory components
in cell di¡erentiation and proliferation as well as in
tissue morphogenesis from £ies to mammals [1,2].
Among the growing number of members of the
TGFL superfamily, which includes bone morphoge-
netic proteins (BMP) and activins, TGFL1 is consid-
ered to represent the prototype factor for character-
izing receptor signaling mechanisms and various
cellular responses. The three mammalian isoforms
TGFL1ÿ3 are highly conserved and functional inter-
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changeable in most biological assays [3,4]. The
growth inhibitory e¡ect of TGFL in a variety of
cell types, in particular in epithelial cells, as well as
its ability to induce gene expression leading to in-
creased extracellular matrix deposition, were charac-
terized by many groups [3,5].
TGFL exerts its activity by interacting with two
types of cell surface serine/threonine kinase recep-
tors, namely type I and type II (TLRI and TLRII)
[6^8]. Both receptors represent transmembrane glyco-
proteins of 55 and 75 kDa, respectively. After ligand
binding to TLRII, the receptor forms a dimer with
TLRI and as a consequence TLRI is phosphorylated
in the GS domain. Concomitantly, the activated ser-
ine/threonine kinase of the receptor type I phosphor-
ylates downstream acting elements, such as Smad
proteins [9,10], which transduce the signal into the
nucleus.
Recent studies revealed the functional importance
of TGFL in various regenerative events [11^13]. In
di¡erent intestinal organs, TGFL is involved in reg-
ulating cell proliferation, di¡erentiation, production
and deposition of extracellular matrix after injury or
in£ammation [14^16]. In contrast to low constitutive
expression of TGFL1ÿ3 in a healthy pancreas, these
growth factors are overexpressed in acute and
chronic pancreatitis. Furthermore, this overexpres-
sion correlates with increased deposition of collagen
and other ECM components [15,17,18]. Recently we
have shown that the inhibition of the biological ac-
tivity of TGFL1 caused a reduction of the collagen
content by 30% in the pancreatitis model used in this
study [19].
The detailed mechanisms by which TGFL is in-
volved in the regulation of ECM turnover are hardly
understood. However, there are supporting data that
TGFL stimulates the expression of various collagen
genes and reduces the expression of extracellular ma-
trix degrading proteases [3,20,21].
In this study, we investigated the in£uence of
TGFL1 on the regulation of its own expression and
on the concentration of the TGFL receptors during
the regenerative process after cerulein-induced pan-
creatitis in vivo as well as in cell culture experiments.
We could demonstrate that TGFL1 stimulated its
own expression and the production of its receptor
proteins type I and type II in the regeneration of
the pancreas as well as in cultured pancreatic cells.
2. Materials and methods
2.1. Materials
Male Wistar rats (150^200 g) were obtained from
the Charles River Laboratories (Sulzbach, Ger-
many). The cDNA probes for rat TGFL receptor
type I (ALK-5) and type II were kindly provided
by Dr. M.G. Brattain (Medical College of Ohio, To-
ledo, USA [22,23]). The TGFL1 cDNA probe was
provided by Dr. R. Dernyck (University of Califor-
nia, San Francisco, USA [24]). The antibody against
TGFL receptors was purchased from UBI (Lake
Placid, USA; [7]). EGFR antiserum was commer-
cially available from Santa Cruz (Santa Cruz,
USA; sc1005). The polyclonal neutralizing anti-
TGFL1 antibody AB-101 from RpD Systems (Min-
neapolis, USA) was used to inhibit the biological
activity of TGFL1. Normal chicken Ig from RpD
Systems served as control serum.
2.2. Induction of experimental pancreatitis
Experimental acute pancreatitis was induced by
intravenous infusion of supramaximal doses of ceru-
lein (Farmitalia, Freiburg, Germany) (10 Wg/kg/h) for
12 h. Control rats were infused with saline. The pro-
tocol was approved by the institutional animal use
and care committee. Serum amylase was measured
daily in order to control the development of the pan-
creatitis as described earlier [25].
To neutralize the activity of TGFL1, the rats re-
ceived three injections (i.v.) of 150 Wg neutralizing
TGFL1 antibody or control serum in PBS. The ¢rst
injection was given 30 min before, the second 24 h
and the third 48 h after start of infusion. Three to
¢ve animals were examined at 0 h (start of infusion),
1, 2, 3, 5 and 7 days after the start of cerulein in-
fusion. The pancreata were quickly removed,
weighed, and shock frozen in liquid nitrogen for fur-
ther studies. All investigations were done in three
unrelated experimental setups.
2.3. RNA studies
The RNA was extracted according to the method
described by Chomczynski and Sacchi [26]. Poly(A)
RNA was isolated with a Qiagen kit in accordance to
BBAMCR 14447 4-3-99
A. Menke et al. / Biochimica et Biophysica Acta 1449 (1999) 178^185 179
the manufacturer’s instructions. For Northern blots
30 Wg total RNA or 6 Wg of poly(A) RNA were
transferred on Hybond-N membranes by capillary
blotting. Equal loading of the slot blots was veri¢ed
by 18S rRNA hybridization. The blots were hybri-
dized with [32P]dCTP labeled puri¢ed cDNA probes
as described earlier [19]. The membranes were ex-
posed to X-ray ¢lms (Kodak XAR, Rochester,
USA) at 370‡C for 7^10 days.
Optical densities of hybridization signals were
measured by using the 1D gel analysis software
from Phoretix (Newcastle upon Tyne, UK). The dif-
ferent cDNA signals were corrected by the optical
densities of the 18S rRNA hybridization of each blot.
2.4. Isolation and culture of pancreatic epithelial cells
Dispersed rat pancreatic cells were prepared by
sequential enzymatic and mechanical dissociation as
described previously [27]. The cells were incubated in
Waymouth medium containing 10% fetal calf serum
(FCS), 1.6 nM EGF, 0.8 nM insulin and 10 nM
choleratoxin. The epithelial origin of the cultured
cells was con¢rmed by immunohistochemical demon-
stration of E-cadherin using an antibody (C20820)
from Transduction Laboratories (Lexington, USA).
After 2 days, the medium was replaced by Way-
mouth medium containing 0.1% FCS for 24 h and
afterwards the cells were stimulated for 18 h with 10
ng/ml TGFL1 (PeproTech, London, UK) in Way-
mouth medium with 0.1% FCS. These cultures
were used for RNA extraction or proliferation as-
says.
2.5. Measurement of DNA synthesis
Cell cultures were stimulated with di¡erent TGFL1
concentrations or control bu¡er for 24 h.
[3H]thymidine incorporation was determined by add-
ing [3H]thymidine (0.5 WCi/ml) for a period of 6 h
during the end of the stimulation period. Subse-
quently, the cells were rinsed by ice-cold PBS, pre-
cipitated with 10% trichloroacetic acid, unprecipi-
tated activity was removed by washing with ice-
cold ethanol (70%). The DNA-bound [3H]thymidine
was solubilized by incubation with 0.5 M NaOH plus
1% SDS and determined in a scintillation counter
(Beckman, Palo Alto, USA). Proliferation in control
medium containing 0.1% FCS was set as 100%, the
cell proliferation data obtained with TGFL1 supple-
mentation were expressed in relation to the controls.
The experiments were measured in quadruplicates
with n = 3.
2.6. Protein determination of TGFL receptors
For protein analysis, the samples were homogen-
ized in RIPA lysis bu¡er (1% Triton X-100, 1% so-
dium deoxycholate, 0.1% SDS, 150 mM NaCl, 50
mM Tris-HCl pH 7.2, 20 mM EDTA) containing
5 WM aprotinin (Bayer-Leverkusen, Leverkusen,
Germany), 1 mM pefabloc, 10 mM leupeptin, 5 mM
vanadate and 5 WM soybean trypsin inhibitor
(all Boehringer-Mannheim, Mannheim, Germany).
SDS-polyacrylamide gel electrophoresis was done ac-
cording to standard procedures [28]. Thirty micro-
grams of protein were separated on each lane. The
fractionated proteins were blotted by semidry techni-
que onto nitrocellulose membranes (Schleicher und
Schu«ll, Dassel, Germany).
For immunodetection, blots were incubated for
1 h at 37‡C with the ¢rst antibody and incubated
30 min with a secondary peroxidase-coupled anti-
serum (Pierce, Rochester, USA). The antibody de-
tection was carried out using the enhanced chemilu-
minescence reaction system (Amersham-Buchler,
Braunschweig, Germany).
3. Results
The development of acute pancreatitis induced by
cerulein infusion was followed up by monitoring se-
rum amylase concentration and morphological ex-
amination of parts of the pancreata as described [25].
As shown earlier [19], quanti¢cation of mRNA
levels of the transforming growth factors revealed
an elevated transcription of TGFL1 peaking at day
2, with a 17-fold expression compared to control
pancreatic tissue (Fig. 1A). This increased mRNA
concentration during regeneration was nearly dimin-
ished by injections of antibody against TGFL1 before
and during induction of pancreatitis by cerulein in-
fusion (Fig. 1A). TGFL receptor type I (TLRI, ALK-
5) and type II (TLRII) mRNAs were expressed at
low levels in the normal pancreas, but 2 days after
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Fig. 1. Expression of TGFL1, TGFL receptor type I and type II during regeneration from cerulein-induced pancreatitis in rats. Neu-
tralization of the biological activity of TGFL1 results in decreased mRNA concentrations as demonstrated by these representative hy-
bridizations. (A) The increased mRNA concentration of TGFL1, 1^5 days after induction of pancreatitis, was diminished by three in-
jections of neutralizing antibody against TGFL1. 18S rRNA is shown as control for equal loading of the gel. (B) Both receptor types
were transcribed at low levels in normal pancreas. After induction of pancreatitis, clearly elevated mRNA levels were detected
(3KTGFL1). This elevated expression was suppressed by TGFL1 antibody injections (+ KTGFL1). The 18S rRNA control hybridiza-
tion is shown in the lower part.
BBAMCR 14447 4-3-99
A. Menke et al. / Biochimica et Biophysica Acta 1449 (1999) 178^185 181
induction of pancreatitis, the concentrations were
signi¢cantly increased for both receptors as shown
in Fig. 1B by representative Northern blot hybrid-
ization. To demonstrate the in£uence of TGFL1 on
the expression of its own receptor, we injected neu-
tralizing antibody against TGFL1 during the induc-
tion of pancreatitis. As a consequence, the increased
expression of the TGFL receptors was completely
reduced by application of a neutralizing antibody
against TGFL1 (Fig. 1B). Additionally to mRNA
quanti¢cation, we examined changes of the protein
concentrations of the receptors during regeneration
by Western blot analyses. We could show that type I
and type II TGFL receptor proteins were expressed
in the normal rat pancreas (Fig. 2A). During the
regeneration period after cerulein-induced pancreati-
tis the concentration of type II receptor was signi¢-
cantly increased within the ¢rst 5 days, whereas the
elevation of type I receptor was less pronounced.
After 3 days, the TLRII concentration reached a
maximum and decreased continuously to control val-
ues at day 7. The same was true in the case of TLRI,
with the maximum at day 5. In contrast to these
¢ndings, no alteration in the EGF receptor content
could be demonstrated. The immunoneutralization
of TGFL1 by a neutralizing antibody also caused a
reduction of TGFL receptor protein expression, but
was less pronounced than the decrease on mRNA
level (Fig. 2B).
In further experiments, the possibility was proved
that TGFL stimulates the expression of its own re-
ceptor by examining the TGFL responsiveness of iso-
lated epithelial cells from the pancreas. The function-
al importance of TGFL1 for these cultured epithelial
cells was shown by its in£uence on cell proliferation
measured by [3H]thymidine incorporation in the
presence or absence of TGFL. TGFL1 reduced the
DNA synthesis in a dose-dependent manner: 10 ng
TGFL1/ml inhibited proliferation of isolated pancre-
atic epithelial cells to about 66% of controls grown in
pure culture medium (Fig. 3A). In parallel samples,
we estimated mRNA concentrations of TGFL1 and
its receptor type I and type II after stimulation with
TGFL1 (10 ng/ml culture medium). As shown in Fig.
3B, the stimulation of cultured pancreatic epithelial
cells resulted in enhanced expression of TGFL1 (13-
fold) and also in elevated mRNA levels of TGFL
receptor type II. Type I receptor again was less over-
expressed in the presence of TGFL1 compared to
TLRII. Examination of the protein concentrations
revealed similar changes. Expression of TLRII was
signi¢cantly elevated after TGFL stimulation in cul-
tured primary epithelial cells, whereas TLRI amounts
showed only a minor increase after stimulation (Fig.
3C).
4. Discussion
The recovery of the pancreas after acute in£amma-
tion, as it is shown for other epithelial organs as well,
is characterized by an increased production of extrac-
ellular matrix proteins [12,29]. It has been shown
previously that 1 day after induction of an acute
Fig. 2. Western blots showing TGFL receptors in the regeneration of the pancreas. (A) As documented for the mRNA, TGFL recep-
tor types I and II concentrations were elevated 3^5 days after induction of pancreatitis. (B) Injection of neutralizing TGFL-antibody
(+ Ab) abolished the increase of TGFL receptors. (C) In contrast to the TGFL receptor, the EGF receptor showed only a slight in-
crease in concentration.
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pancreatitis in rats TGFL1 and TGFL2 were signi¢-
cantly overexpressed with a maximum on the second
day [15,19]. In agreement with data from the litera-
ture on experimental glomerulonephritis and wound
scarring [30,31], we have shown that this transient
¢brosis can be dramatically altered by inhibiting
the biological activity of TGFL1, one of the most
prominent regulators in extracellular matrix turnover
in many tissues [19]. The injection of neutralizing
antibody against TGFL1 during induction of acute
pancreatitis reduced the mRNA level of TGFL1
and the expression and deposition of collagen type
I, type III and ¢bronectin [19], suggesting a success-
ful inhibition of TGFL activity. Most recently, it was
shown that pancreatic stellate cells, which were regu-
lated by TGFL, represents the main producer of ex-
tracellular matrix [32]. The process of collagen de-
position was paralleled by increased expression of
matrix metalloproteases (MMPs), which are also
regulated by TGFL1. Especially MMP-2 and
MMP-3 [33] were involved in the subsequent degra-
dation of the ECM. Therefore TGFL1 seems to be
one factor leading to a coordinated action of colla-
gen production, deposition and following degrada-
tion during pancreatic regeneration.
The results shown here demonstrated that TGFL1
enhanced its signal transduction activity by upregu-
lation of the expression of its own receptors during
regeneration after acute pancreatitis. TLRI and
TLRII mRNA levels were remarkably increased on
day 2 after induction of pancreatitis, whereas protein
levels reached their maxima on day 3, respectively.
Fig. 3. Stimulation of cultured epithelial cells of the pancreas
with TGFL1 revealed reduced proliferation and altered mRNA
levels. (A) Cell proliferation of primary epithelial cells, meas-
ured by [3H]thymidine incorporation, was decreased by TGFL1
in a dose-dependent manner. Thymidine incorporation in me-
dium without TGFL1 was set as 100%, inhibition by TGFL was
expressed in relation to the controls (mean þ S.E.M., n = 3). (B)
Expression levels of TGFL1 and TGFL receptor type I and II
were also increased under these in vitro conditions. TGFL1 and
TLRII mRNA were signi¢cantly elevated (13- and 2.9-fold),
whereas the type I receptor exhibited only minor increase (1.7-
fold). In the lower part, 18S rRNA hybridization is shown doc-
umenting equal amounts of RNA. (C) Similar changes were
found for protein concentrations of TLRI and RII after TGFL1
stimulation. Western blot analyses showed signi¢cantly elevated
amounts of TLR type II and a lower increase in case of type I.
6
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These data correlate well with the elevated expression
of collagen with its maximum at day 3 as shown
before [19], supporting the regulatory in£uence of
TGFL via its receptors on collagen contents. Imme-
diately after their expression maxima collagen,
TGFL1 and the TGFL receptor mRNA concentra-
tions declined to control values. For the ¢rst time
we show that TGFL is able to promote the expres-
sion of its own receptors, a process which is well
known in growth factor signaling via receptor-tyro-
sine kinases, such as basic ¢broblasts growth factor
(bFGF) or hepatocyte growth factor (HGF), but not
described for receptor-serine/threonine kinases. Stim-
ulation of ¢broblasts and epithelial cells with bFGF
or HGF led to elevated expression of the FGF re-
ceptor 2 or c-met, the HGF receptor respectively [34^
36].
Neutralization of TGFL1 activity caused decreased
mRNA and protein concentrations of TGFL recep-
tor type I and type II during regeneration after ex-
perimentally induced acute in£ammation. These re-
sults were con¢rmed by in vitro data using cultured
primary epithelial cells. In this experiment, TGFL1
positively regulated its own synthesis and the expres-
sion of its receptors. Cultured pancreatic cells upon
TGFL stimulation exhibited a lower increase in re-
ceptor expression than observed in vivo. These small
di¡erences may be explained by more de¢ned condi-
tions in cell culture, where we analyzed only the
TGFL e¡ects on epithelial cells. In contrast to the
cell culture model, cells in a complete organ are in-
£uenced by complex interactions of growth factors,
cytokines and di¡erent cell types leading to intensi-
¢ed signals.
As shown by others, TGFL stimulation leads to
enhanced expression of Smad proteins, the intracel-
lular mediators of the TGFL pathway [37^39]. Alto-
gether these results implicate that TGFL1 ampli¢ed
its biological e¡ects by a self-stimulated production.
Additionally, the increased production of its recep-
tors and intracellular signaling mediators potentiated
the sensitivity of the TGFL cascade, at least in epi-
thelial cells.
Pancreatic epithelial cells seem to contribute to
regenerative processes by autocrine and paracrine
TGFL-induced mechanisms. Autocrine stimulation
of epithelial cells led to reduced proliferation, while
paracrine stimulation of stellate cells induced pro-
duction of ECM components. In line with these
data, the neutralization of TGFL1 during pancreati-
tis, as reported before [19], led to a slightly acceler-
ated regeneration of the pancreas, due to reduced
transient ¢brosis and non-inhibited epithelial prolif-
eration.
In addition to regeneration after in£ammation, Oft
and colleagues recently showed that in late-stage
events of carcinogenesis, a cell-autonomous signaling
via TGFL is required for the invasive growth of tu-
mor cells, most probably mediated by autocrine
loops involving TGFL and TGFL receptors [40].
In summary, these data suggest the important role
of TGFL1 as a key regulator in control of cell pro-
liferation and induction of enormous expression and
synthesis of collagen and other ECM components
observed in pancreatitis. The TGFL e¡ects on epi-
thelial pancreatic cells are potentiated by autocrine
and/or paracrine stimulated growth factor synthesis
and TGFL-induced expression of its cellular recep-
tors.
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